Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Cabozantinib and nivolumab were associated with limited response in patients with epNET. Alternative strategies to enhance the immune response in epNET are needed.
Authors
- Kimberly J. Perez (ORCID: https://orcid.org/0000-0002-5745-2994)
- Anuj Patel (ORCID: https://orcid.org/0000-0002-7045-6957)
- Marta Holovatska (ORCID: https://orcid.org/0000-0002-0291-4960)
- Matthew H. Kulke (ORCID: https://orcid.org/0000-0001-8556-3977)
- Joanna Bagińska (ORCID: https://orcid.org/0000-0001-5182-7575)
- Douglas A. Rubinson (ORCID: https://orcid.org/0000-0002-5337-5231)
- Thomas A. Abrams (ORCID: https://orcid.org/0000-0003-3101-1573)
- Scott J. Rodig (ORCID: https://orcid.org/0000-0003-1761-9769)
- Benjamin L. Schlechter (ORCID: https://orcid.org/0000-0002-1529-3278)
- Allison Nau
- Anita Giobbie‐Hurder (ORCID: https://orcid.org/0000-0003-2496-7737)
- Ian Dryg (ORCID: https://orcid.org/0000-0001-6173-2000)
- Nora Horick (ORCID: https://orcid.org/0000-0002-4355-5853)
- Kathleen L. Pfaff (ORCID: https://orcid.org/0000-0003-3311-5384)
- F. Stephen Hodi (ORCID: https://orcid.org/0000-0001-6825-091X)
- Mark Redston (ORCID: https://orcid.org/0000-0001-9055-8857)
- Ilana Gomez Diaz
- Alexandra Bird (ORCID: https://orcid.org/0009-0007-0749-0873)
- Jennifer Ang Chan (ORCID: https://orcid.org/0000-0003-2523-9598)
Institutions
- Brigham and Women's Hospital (US)
- Boston Medical Center (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2337
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00